Evaluation of Paxillin Expression in Epithelial Dysplasia, Oral Squamous Cell Carcinoma, Lichen Planus with and without Dysplasia, and Hyperkeratosis: A Retrospective Cross-Sectional Study.
carcinomatosis
dysplasia
lichen planus
paxillin
squamous cell carcinoma
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
25 Jul 2023
25 Jul 2023
Historique:
received:
30
06
2023
revised:
21
07
2023
accepted:
24
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Paxillin is a cytoskeletal protein involved in the pathogenesis of several types of cancers. However, the roles of paxillin in epithelial dysplasia (ED), oral squamous cell carcinoma (OSCC), oral lichen planus with dysplasia (OLPD), hyperkeratosis (HK), and oral lichen planus (OLP) have remained unnoticed in the literature. This study aimed to evaluate its attainable functions in the pathogenesis and malignant transformation of potentially malignant oral epithelium and benign lesions. In this retrospective cross-sectional study, paxillin expression was investigated in 99 tissue samples, including 18 cases of OSCC, 21 ED, 23 OLP, 21 OLPD, and 16 cases of HK. The tissue sections also underwent immunohistochemical paxillin staining using 3,3-diaminobenzidine (DAB) chromogen. The intensity, location, and percentage of staining were examined across all groups. Data were analyzed using the Shapiro-Wilk test, ANOVA, Pearson chi-square, Kruskal-Wallis, and Dunn's post hoc test. The cytoplasmic percentage and intensity staining of Paxillin expression were evident in the central/suprabasal and basal/peripheral layers of all the obtained samples. The final staining score was significantly higher in OSCC and dysplasia compared to HK and OLP ( The present study provides evidence that paxillin may be involved in the pathogenesis of OSCC and the development and progression of dysplastic tissue, since the paxillin expression was higher than that of HK and OLP.
Sections du résumé
BACKGROUND
BACKGROUND
Paxillin is a cytoskeletal protein involved in the pathogenesis of several types of cancers. However, the roles of paxillin in epithelial dysplasia (ED), oral squamous cell carcinoma (OSCC), oral lichen planus with dysplasia (OLPD), hyperkeratosis (HK), and oral lichen planus (OLP) have remained unnoticed in the literature. This study aimed to evaluate its attainable functions in the pathogenesis and malignant transformation of potentially malignant oral epithelium and benign lesions.
METHODS
METHODS
In this retrospective cross-sectional study, paxillin expression was investigated in 99 tissue samples, including 18 cases of OSCC, 21 ED, 23 OLP, 21 OLPD, and 16 cases of HK. The tissue sections also underwent immunohistochemical paxillin staining using 3,3-diaminobenzidine (DAB) chromogen. The intensity, location, and percentage of staining were examined across all groups. Data were analyzed using the Shapiro-Wilk test, ANOVA, Pearson chi-square, Kruskal-Wallis, and Dunn's post hoc test.
RESULTS
RESULTS
The cytoplasmic percentage and intensity staining of Paxillin expression were evident in the central/suprabasal and basal/peripheral layers of all the obtained samples. The final staining score was significantly higher in OSCC and dysplasia compared to HK and OLP (
CONCLUSION
CONCLUSIONS
The present study provides evidence that paxillin may be involved in the pathogenesis of OSCC and the development and progression of dysplastic tissue, since the paxillin expression was higher than that of HK and OLP.
Identifiants
pubmed: 37568839
pii: diagnostics13152476
doi: 10.3390/diagnostics13152476
pmc: PMC10417688
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Res. 1999 Jun 15;59(12):2843-6
pubmed: 10383144
Sao Paulo Med J. 2013;131(2):71-9
pubmed: 23657508
Arch Oral Biol. 2023 Feb;146:105589
pubmed: 36442338
Biomed Rep. 2018 Oct;9(4):275-283
pubmed: 30233779
J Basic Microbiol. 2023 Aug;63(8):831-854
pubmed: 37173818
Oral Dis. 2008 Apr;14(3):229-43
pubmed: 18298420
J Dent (Shiraz). 2019 Dec;20(4):249-254
pubmed: 31875171
Dent Clin North Am. 2014 Apr;58(2):315-40
pubmed: 24655525
J BUON. 2017 Sep-Oct;22(5):1097-1106
pubmed: 29135089
J Hematol Oncol. 2017 Feb 18;10(1):50
pubmed: 28214467
J Biol Chem. 2012 Sep 21;287(39):32566-77
pubmed: 22869380
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103 Suppl:S25.e1-12
pubmed: 17261375
Mol Med Rep. 2019 Oct;20(4):3509-3518
pubmed: 31485648
Otolaryngol Clin North Am. 2006 Apr;39(2):277-94
pubmed: 16580911
Oral Oncol. 1999 Mar;35(2):151-6
pubmed: 10435149
Photobiomodul Photomed Laser Surg. 2023 Jun;41(6):248-264
pubmed: 37222762
Arch Dermatol. 1970 Sep;102(3):253-9
pubmed: 5456015
J Int Med Res. 2008 Mar-Apr;36(2):273-8
pubmed: 18380937
Histopathology. 2011 Oct;59(4):733-40
pubmed: 21916948
J Oral Pathol Med. 2010 Aug 1;39(7):548-51
pubmed: 20136697
Arch Oral Biol. 2021 May;125:105090
pubmed: 33676362
J Dent Res. 2018 Jun;97(6):635-644
pubmed: 29489434
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Sep;112(3):328-34
pubmed: 21782485
Med Oncol. 2023 Feb 7;40(3):91
pubmed: 36749489
J Clin Pathol. 2011 Jan;64(1):16-24
pubmed: 21045234
Immun Inflamm Dis. 2023 Mar;11(3):e812
pubmed: 36988245
PLoS One. 2012;7(11):e50710
pubmed: 23209815
Oral Dis. 2021 Nov;27(8):1862-1880
pubmed: 33128420
Oral Oncol. 2007 Jul;43(6):523-34
pubmed: 17258495
Int J Mol Sci. 2020 Oct 30;21(21):
pubmed: 33143101
J Pharm Bioallied Sci. 2015 Apr;7(Suppl 1):S158-61
pubmed: 26015696
Int J Cancer. 1996 Oct 9;68(2):164-71
pubmed: 8900422
Protein Eng. 1997 Jan;10(1):1-6
pubmed: 9051728
FEBS Lett. 2002 Feb 20;513(1):114-8
pubmed: 11911889
Am J Pathol. 2003 Aug;163(2):753-62
pubmed: 12875994
Oral Oncol. 2005 Sep;41(8):757-75
pubmed: 16109353
Int J Mol Sci. 2022 Jan 29;23(3):
pubmed: 35163485
Gastroenterology. 2006 Sep;131(3):830-40
pubmed: 16952552
Cancer Res. 2008 Jan 1;68(1):132-42
pubmed: 18172305
Pathol Res Pract. 2017 Jul;213(7):809-814
pubmed: 28554768
J Mol Signal. 2008 Jan 02;3:1
pubmed: 18171471
Noncoding RNA Res. 2022 Nov 22;8(1):109-114
pubmed: 36474750
J Cell Sci. 2008 Aug 1;121(Pt 15):2435-44
pubmed: 18650496
Otolaryngol Head Neck Surg. 2007 Mar;136(3):401-4
pubmed: 17321867
J Clin Diagn Res. 2017 Jul;11(7):ZC56-ZC58
pubmed: 28893044
Head Neck. 2009 Dec;31(12):1600-9
pubmed: 19455705
Oncogene. 2001 Nov 29;20(55):7976-86
pubmed: 11753680
Oncotarget. 2016 May 24;7(21):31586-601
pubmed: 26980710
J Basic Microbiol. 2023 Jun 13;:
pubmed: 37311215
J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):19-27
pubmed: 31110412
Hum Pathol. 2006 Jan;37(1):9-15
pubmed: 16360410
Oral Oncol. 2001 Sep;37(6):477-92
pubmed: 11435174
Urol Oncol. 2013 Aug;31(6):836-42
pubmed: 21868260
Med Oral Patol Oral Cir Bucal. 2010 Sep 01;15(5):e685-90
pubmed: 20383118
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Nov;110(5):618-23
pubmed: 20875757
J Formos Med Assoc. 2018 Sep;117(9):756-765
pubmed: 29472048
J Oral Maxillofac Pathol. 2017 May-Aug;21(2):318-319
pubmed: 28932050
Oral Oncol. 2013 Sep;49(9):854-862
pubmed: 23876628
Oral Oncol. 2020 Mar;102:104550
pubmed: 31981993
Head Neck. 1998 Oct;20(7):634-9
pubmed: 9744465
Biochem Biophys Res Commun. 2001 Aug 24;286(3):601-8
pubmed: 11511102
Cancer Causes Control. 1990 Nov;1(3):235-41
pubmed: 2102296
J Craniofac Surg. 2013 May;24(3):788-91
pubmed: 23714881
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Aug;96(2):164-71
pubmed: 12931088
J Oral Pathol Med. 2010 Nov;39(10):729-34
pubmed: 20923445
J Oral Maxillofac Pathol. 2022 Jul-Sep;26(3):322-329
pubmed: 36588853